JY
NRIX icon

Jeff Yass’s Nurix Therapeutics NRIX Stock Holding History

Jeff Yass’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
57,800
+43,400
+301% +$739K ﹤0.01% 7320
2026
Q1 		$223K Sell
14,400
-48,400
-77% -$803K ﹤0.01% 11482
2025
Q4 		$1.19M Buy
+62,800
New +$902K ﹤0.01% 6793
2025
Q1 		– Sell
-32,700
Closed -$616K – 13140
2024
Q4 		$616K Sell
32,700
-10,700
-25% -$245K ﹤0.01% 8169
2024
Q3 		$975K Sell
43,400
-26,400
-38% -$598K ﹤0.01% 6843
2024
Q2 		$1.46M Buy
69,800
+51,400
+279% +$800K ﹤0.01% 5744
2024
Q1 		$270K Buy
+18,400
New +$198K ﹤0.01% 9937
2023
Q3 		– Sell
-10,200
Closed -$102K – 12646
2023
Q2 		$102K Buy
+10,200
New +$104K ﹤0.01% 10934

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's NRIX Position: Q2 2026 in Review

Jeff Yass reduced its Nurix Therapeutics (NRIX) stake by 53% in Q2 2026, selling an estimated $739K and leaving 38,080 shares worth $924K. The position accounts for ﹤0.01% of the portfolio, ranked #8393.

Jeff Yass first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.77M in Q1 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Jeff Yass held 38,080 shares of Nurix Therapeutics worth $924K as of Q2 2026.
  • Jeff Yass sold 43,375 Nurix Therapeutics shares in Q2 2026, an estimated $739K.
  • Nurix Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8393 holding.
  • Jeff Yass first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Jeff Yass's Nurix Therapeutics position peaked at $1.77M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.